Navigation Links
Rheumatoid Arthritis Drugs Price Analysis and Strategies 2012-2016 & Forecasts to 2021 -Research and Markets
Date:2/28/2017

DUBLIN, Feb 28, 2017 /PRNewswire/ --


Research and Markets has announced the addition of the "Rheumatoid Arthritis Drugs Price Analysis and Strategies - 2016" report to their offering.

The latest research Rheumatoid Arthritis Drugs Price Analysis and Strategies - 2016, provides drug pricing data and benchmarks in the global Rheumatoid Arthritis market.

The research answers the following questions:

  • What are the key drugs marketed for Rheumatoid Arthritis and their clinical attributes? How are they positioned in the Global Rheumatoid Arthritis market?
  • What are the unit prices and annual treatment cost for Rheumatoid Arthritis therapies in different countries? What are the drug pricing trends and how are they expected to change in the future? How are the drug pricing and reimbursement landscape different by countries?
  • What are the unmet needs in the global Rheumatoid Arthritis drugs market? What would be the ideal pricing strategy for a new pipeline therapy for Rheumatoid Arthritis?

Research Scope:

  • Rheumatoid Arthritis Treatment Options - Identify key drugs marketed and prescribed for Rheumatoid Arthritis in the US, Germany, France, Italy, Spain, UK, Japan including trade name, molecule name, and company
  • Rheumatoid Arthritis Drugs Attributes - Find out the safety, efficacy, and risk benefit for key drugs marketed for Rheumatoid Arthritis
  • Market Positioning - Identify how drugs are clinically and commercially positioned in the global Rheumatoid Arthritis market
  • Rheumatoid Arthritis Drugs Price Analysis - Find out the annual therapy cost and unit price for key drugs marketed for Rheumatoid Arthritis in the US, Germany, France, Italy, Spain, UK, Japan. Find out how the price advanced from 2012 and forecast to 2021
  • Pricing & Reimbursement Landscape - Find out the pricing and reimbursement landscape in the US, Germany, France, Italy, Spain, UK, Japan
  • Rheumatoid Arthritis New Drug Pricing - Identify the effective pricing strategy for a new drug launch in the US, Germany, France, Italy, Spain, UK, Japan

This research will help executives

  • Identify clinical attributes of your competitor drugs
  • Find out how the marketed products for Rheumatoid Arthritis are clinically and commercially positioned
  • Understand the price of your competitor drugs by countries
  • Use Rheumatoid Arthritis drugs price data for market sizing, drug sales forecast, budgeting, competitive intelligence, HEOR, and reimbursement
  • Find out the pricing and reimbursement landscape by countries
  • Identify the unmet need in global Rheumatoid Arthritis market
  • Identify the effective pricing for a new drug

For more information about this report visit http://www.researchandmarkets.com/research/vjsw3w/rheumatoid

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com 

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716



To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rheumatoid-arthritis-drugs-price-analysis-and-strategies-2012-2016--forecasts-to-2021--research-and-markets-300414740.html


'/>"/>
SOURCE Research and Markets
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Rheumatoid Arthritis Patients are Moderately to Highly Satisfied with Their Current Drug Therapy, Rating Conventional DMARDs Highest on Ease of Use and Cost
2. Five-Year SIMPONI Data Reported In Treatment Of Signs And Symptoms Of Moderately To Severely Active Rheumatoid Arthritis
3. U.S. and European Rheumatologists Agree That a Therapys Induction of Remission is One of the Attributes That Most Influences Their Prescribing Decisions in Rheumatoid Arthritis
4. Pain Management Therapeutics Market to 2019 - Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline
5. MCOs Shifting Control Over Office-Administered Products from Medical to Pharmacy Benefit, Particularly Affecting Rheumatoid Arthritis Therapies
6. Isis Pharmaceuticals Reports Data From a Phase 2 Study of Isis-CRP Rx in Patients with Rheumatoid Arthritis
7. Surveyed U.S. Rheumatologists are Moderately Satisfied with Biologic Agents and Xeljanz to Treat Rheumatoid Arthritis
8. Hospira Shares Results From Two Open-label Extension Studies for Biosimilar Infliximab in Patients With Rheumatoid Arthritis or Ankylosing Spondylitis
9. Sanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial
10. Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis
11. Global Rheumatoid Arthritis Drugs Market 2014-2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2019)... ... May 22, 2019 , ... Ahead of the opening ... today its partnership with Osmosis, the leading medical education platform with more than one ... industry. With an impending shortage of more than 120,000 clinicians by 2030, the Fort ...
(Date:5/22/2019)... (PRWEB) , ... May 22, 2019 , ... ... that it has partnered with Women In Bio of Southern California (WIB-SoCal) to ... accomplished female scientists, past and present, will be featured in a joint social ...
(Date:5/22/2019)... ... 2019 , ... For two days, the American Parkinson Disease Association (APDA) ... for their annual meeting to review grant requests and determine which cutting-edge research ... researchers and neurologists with specialized interest in the field of diversity at the first-ever ...
Breaking Medicine Technology:
(Date:5/22/2019)... ... May 22, 2019 , ... Antiperspirant manufacturer Carpe announced the ... sweat and friction. The powder comes in a compact 10 gram container with ... portability. , “Groin sweat and the chafing it can cause are an uncomfortable ...
(Date:5/22/2019)... ... 22, 2019 , ... EY today announced that Bob Arnesen, ... the Entrepreneur Of The Year® 2019 Award in the New England region. Widely ... program recognizes entrepreneurs and leaders of high-growth companies who are excelling in areas ...
(Date:5/22/2019)... ... May 22, 2019 , ... There are over 2.3 million ... are living with MS today and 10,000 new cases are diagnosed each year. The ... than ever. , MS is difficult to diagnose and manage due to a lack ...
(Date:5/22/2019)... , ... May 22, 2019 , ... The Power of ... The fashion expert and creator shares seven ways for women to step into their ... Power of Color combines spirituality, music, and dancing to further self-expression. Women looking to ...
(Date:5/21/2019)... ... May 21, 2019 , ... In a drive for ... Century Cure Act[2], calls for the identification and refinement of a basic set ... Medical Informatics Association; however, recommends that healthcare researchers and providers concentrate on sharing ...
Breaking Medicine News(10 mins):